Journal for ImmunoTherapy of Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-03-02 ms3000001679871516 来自山西省

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤免疫
经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。

13 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-04-30 酸萝卜别吃来自吉林省

前往app查看评论内容

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-03-14 145a3c37m10暂无昵称来自上海

修回快一周了还在技术审查。这个阶段要多久啊

20 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-03-19 ms6000000038850532 来自湖北省

偏重的研究方向：机制;肿瘤免疫
经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受

11 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-04-09 ms2000000899762473 来自江苏省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤免疫治疗
经验分享：9月17投稿
10月31开始大修
1月31修回
2月6号小修
2月23号修回
2月26号接收

10 0

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-02-23 ms9000000350023872

偏重的研究方向：肿瘤免疫
经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢

30 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-03-23 ms7000001136469102 来自广东省

2025年分区降了吗

13 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-03-14 ms9000000350023872

审稿速度:3.0
经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的

24 0

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-01-25 ms9000000459040319 来自山东省

为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection

17 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2254271, encodeId=d95c22542e1c8, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤免疫 经验分享：2月4日投了一篇case report，状态一直是Awaiting reviewer selection，3月2日发现awaiting recommendation，是要拒稿吗，这期间没有看到Awaiting reviewer assigned。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4df9026364, createdName=ms3000001679871516, createdTime=Sun Mar 02 17:52:07 CST 2025, time=2025-03-02, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2262859, encodeId=e0602262859d2, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72185230239, createdName=酸萝卜别吃, createdTime=Wed Apr 30 08:46:20 CST 2025, time=2025-04-30, status=0, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2256007, encodeId=32bf225600e45, content=修回快一周了还在技术审查。这个阶段要多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202501/6bb68c9ce3d34f46bd8e59f3ce52814d-AvbX3iEBHoXO.png, createdBy=a9db5076465, createdName=145a3c37m10暂无昵称, createdTime=Fri Mar 14 08:23:22 CST 2025, time=2025-03-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2256707, encodeId=faa92256e07af, content=偏重的研究方向：机制;肿瘤免疫 经验分享：分享一下期刊最近的接受速度。祝大家都能有个好结果。 10.23 投稿 10.31 决定送外审 11.23 一审大修 1.20 修回 3.1 二审小修 3.3 修回 3.10 三审小修，当天修回 3.16 顺利接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=749e9492476, createdName=ms6000000038850532, createdTime=Wed Mar 19 09:33:57 CST 2025, time=2025-03-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2259800, encodeId=ca352259800b6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤免疫治疗 经验分享：9月17投稿 10月31开始大修 1月31修回 2月6号小修 2月23号修回 2月26号接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=febe9432725, createdName=ms2000000899762473, createdTime=Wed Apr 09 21:33:02 CST 2025, time=2025-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2253126, encodeId=7e7e2253126d9, content=偏重的研究方向：肿瘤免疫 经验分享：Awaiting Reviewer Assignment这个状态能持续多久啊，都一个月了，真是受不了，还等着毕业呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Sun Feb 23 00:30:47 CST 2025, time=2025-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257357, encodeId=5955225e357dc, content=2025年分区降了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14c65506441, createdName=ms7000001136469102, createdTime=Sun Mar 23 09:49:08 CST 2025, time=2025-03-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256039, encodeId=2292225603917, content=审稿速度:3.0 经验分享：为什么审稿人意见都回来以后编辑一直不处理呢，都十天了，别人都是当天就处理的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de716150836, createdName=ms9000000350023872, createdTime=Fri Mar 14 11:25:20 CST 2025, time=2025-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2249545, encodeId=3ffe2249545ff, content=为啥经历大修、小修，小修修回后20填了还在awaiting reviewers assignment/ Selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05945501388, createdName=ms9000000459040319, createdTime=Sat Jan 25 09:42:51 CST 2025, time=2025-01-25, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2248933, encodeId=74322248933cf, content=偏重的研究方向：肿瘤免疫 经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea259213833, createdName=ms6000002098058965, createdTime=Mon Jan 20 19:32:06 CST 2025, time=2025-01-20, status=1, ipAttribution=湖北省)]

2025-01-20 ms6000002098058965 来自湖北省

偏重的研究方向：肿瘤免疫
经验分享：请问各位大佬，修回时的response那里是既要复制上去又要传word文件吗

16 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务